A phase III, open-label, single-dose study to evaluate the safety and immunogenicity of Fluviral trivalent split virion influenza vaccine (2007-2008 season) in adults ranging in age from 18 to 60 years and 61 years and over.
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2016
At a glance
- Drugs GSK 1536489A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 09 Oct 2007 Status change from in progress to completed
- 18 Aug 2007 New trial record.